General
Preferred name
IBREXAFUNGERP
Synonyms
SCY-078 ()
Ibrexafungerp (citrate) ()
MK 3118 (citrate) ()
SCY-078 (citrate) ()
MK 3118 ()
MK-3118 FREE BASE ()
MK3118 ()
MK-3118 ()
Brexafemme ()
SCY-078 citrate ()
IBREXAFUNGERP CITRATE ()
P&D ID
PD058025
CAS
1207753-03-4
1965291-08-0
Tags
available
drug
Approved by
FDA
First approval
2021
Drug indication
Fungal infection
Invasive candidiasis
Aspergillosis
Vulvovaginal Candidiasis
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 3454
DESCRIPTION Ibrexafungerp (MK 3118) is an orally active ??-1,3-glucan synthase inhibitor with antifungal activity, disrupting fungal cell wall integrity, used in fungal infection research.
DESCRIPTION Ibrexafungerp citrate (MK 3118 citrate) is an orally active ¦Â-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].
Compound Sets
8
ChEMBL Approved Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
MedChem Express Bioactive Compound Library
External IDs
50
Properties
(calculated by RDKit )
Molecular Weight
729.52
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
7
Aromatic Ring Count
2
cLogP
8.62
TPSA
125.38
Fraction CSP3
0.77
Chiral centers
12.0
Largest ring
6.0
QED
0.26
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Fungal
Pathway
Anti-infection
Source data